SCHEMBL18484126

SCHEMBL18484126

Cc1cccnc1N1CC(O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
TRPV1 Q8NER1 2/20 0.43
SMO Q99835 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
DRD4 P21917 1/20 0.39
PDE10A Q9Y233 1/20 0.39
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
HTR7 P34969 1/20 0.38
MALT1 Q9UDY8 1/20 0.38
KMT2A Q03164 1/20 0.38
LCAT P04180 1/20 0.38
AVPR1A P37288 1/20 0.38
F13A1 P00488 1/20 0.38
TGM2 P21980 1/20 0.38
TGM1 P22735 1/20 0.38
TGM3 Q08188 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31716179 1.00 HSD11B1 (0.44) HSD11B1TRPV1SMOKDM4ENPC1
SCHEMBL14818776 0.89 HSD11B1 (0.44) HSD11B1TRPV1KDM4ENPC1RAB9A
SCHEMBL11962835 0.87 SMO (0.48) HSD11B1TRPV1SMOPDE10AMALT1
SCHEMBL20244837 0.84 HSD11B1 (0.46) HSD11B1TRPV1NOS3NOS1NOS2
SCHEMBL3436511 0.83 SMO (0.53) HSD11B1TRPV1SMOKDM4EDRD4
SCHEMBL3436628 0.79 HSD11B1 (0.49) HSD11B1TRPV1SMOKDM4EDRD4
SCHEMBL15966074 0.79 ALDH1A1 (0.46) HSD11B1KDM4EKMT2A
SCHEMBL18484125 0.79 PDE10A (0.39) PDE10AKMT2A
SCHEMBL4880417 0.79 PDE10A (0.39) TRPV1PDE10AMALT1KMT2A
SCHEMBL14207437 0.79 GRIN2D (0.50) HSD11B1KDM4EPDE10AMALT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 US disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
WO-2017022861-A1 SUBSTITUTED GUANIDINE DERIVATIVE 宇部興産株式会社 2017-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 HSD11B1 3409/4885TRPV1 4843/4885SMO 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.